Thank you, Maria. Yes, I will now comment on the third quarter of 2024.
All numbers are presented in Swedish crowns.
I would also like to remind you that from the first quarter of this year, BICO reports in functional reporting and comparable numbers have been adjusted. Furthermore, all organic growth figures are in constant currency. As Maria mentioned, BICO delivered sales of 496 million with an organic growth of -13%. And I will comment more on sales on the next slide. Adjusted EBITDA amounted to 40 million, and EBITDA was 37 million for the quarter. We also have a separate slide where I will present the Q3 EBITDA development. Gross margin for the quarter amounted to 53%, which is an improvement compared to previous quarters and can be explained by the product mix with fewer projects. The project-related business in Lab Automation. The net loss for the quarter amounted to -248 million.
On the next slide, I will comment on sales for the group for the third quarter.
As mentioned, the third quarter generated sales of 496 million, corresponding to a negative sales growth of 16% and a negative organic growth of 13%, compared to a very strong corresponding quarter last year.
Year to date, sales amounted to 1,540,000,000, corresponding to a negative organic growth of 4% compared to last year. In the quarter, the market has continued to be soft for instrument sales, primarily in the academia, research, and diagnostic segments due to ongoing customer CapEx constraints. Additionally, during the quarter, we had fewer project starts in Lab Automation, negatively impacting our sales. As mentioned in our CMD, one of the rationales for including Bio Zero in a separate business area was to increase the transparency of BICO's financial profile, as Bio Zero has a different business model and financial profile compared to our instrument companies due to its project-based business, with significant fluctuations in revenues depending on project starts. Primarily, this relates to BioZero having a percentage of completion revenue recognition model, which creates significant revenues when a project is started and when instruments for the projects are typically acquired. And as mentioned, in this quarter we had fewer project starts, impacting revenues negatively. Furthermore, for the quarters to come, Lab Automation will have tough comparable figures due to the large order of $28 million at the end of 2023, which had a significant positive effect on the first half of 2024 financials. Maria will comment in detail on the business areas to give you some more in-depth information, especially with regards to Lab Automation and the project-based business models.
Lastly, unlike many of our industry peers, we have seen improved sales in our companies that are more focused on consumable sales. And if we move on to profitability, adjusted EBITDA for Q3 amounted to 40 million, corresponding to a margin of 8%. EBITDA amounted to 30 million, also corresponding to a margin of 8%. All business areas were profitable in the quarter. The margin drop of 8% is explained by weaker sales development compared to last year and, as previously mentioned, driven by a continued weak market in the academia, research, and diagnostics segments due to ongoing CapEx constraints as well as fewer project starts in Lab Automation. This decrease in sales was partially offset by better cost control, an improved product mix, and lower personnel costs. As always, and it's worth repeating, staying on course with cost control is a priority across the group. Staying on course with cost control is always a priority across the group.
And if we move on to the next slide and our cash flow, the cash flow from operating activities for the quarter amounted to 45 million.
This includes a positive effect from changes in working capital of 33 million.
Out of this, 17 million was related to increases in operating receivables. Inventories decreased by 90 million, continuing the positive trend of decreased inventory, and operating liabilities increased by 31 million. Investments in tangible CapEx amounted to 10 million, and investments in intangible CapEx amounted to 17 million for the second quarter in a row. We didn't pay out any earnouts. Total estimated remaining earn-out payments amounted to 8 million. Total cash flow during Q3 amounted to -1 million, and cash reserves by the end of September amounted to 682 million. This slide shows the development in net working capital between Q3 2023 and 2024.
During this period, net working capital has decreased from 550 million to 456 million and has been stable between 20 to 24% of sales.
To conclude, BICO has for the past quarters shown that the actions implemented in 2023 to improve working capital were successful. We have continued to work diligently on this during the year as part of our operational excellence activities, and because the levels of net working capital are now in line with industry peers. Maria will now comment on our three business areas. Performances.